Open Access

An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report

  • Piero Valentini1,
  • Gabriella Parisi2,
  • Monica Monaco3,
  • Francesca Crea1,
  • Teresa Spanu4,
  • Orazio Ranno1,
  • Mirella Tronci2 and
  • Annalisa Pantosti3Email author
Annals of Clinical Microbiology and Antimicrobials20087:11

DOI: 10.1186/1476-0711-7-11

Received: 05 February 2008

Accepted: 30 April 2008

Published: 30 April 2008

Abstract

Background

Methicillin resistant Staphylococcus aureus (MRSA) has been considered for many years a typical nosocomial pathogen. Recently MRSA has emerged as a frequent cause of infections in the community. More commonly, community-acquired (CA)-MRSA is a cause of infections of the skin and soft-tissues, but life-threatening infections such as necrotizing pneumonia and sepsis can occasionally occur.

Case presentation

This report describes an uncommon presentation of invasive CA-MRSA infection in an adolescent without known risk factors. The presentation was typical for bacterial meningitis, but the clinical findings also revealed necrotizing pneumonia. Following the development of deep venous thrombosis, the presence of an inherited trombophilic defect (factor V Leiden) was detected. The patient was successfully treated with an antibiotic combination including linezolid and with anticoagulant therapy. CA-MRSA was isolated from both cerebrospinal fluid and blood. The isolates were resistant to oxacillin and other beta-lactam antibiotics and susceptible to the other antibiotics tested including erythromycin. Molecular typing revealed that the strains contained the Panton-Valentine leukocidin genes and type IV SCCmec, and were ST8, spa type t008, and agr type 1. This genetic background is identical to that of the USA300 clone.

Conclusion

This report highlights that meningitis can be a new serious presentation of CA-MRSA infection. CA-MRSA strains with the genetic background of the USA300 clone are circulating in Italy and are able to cause severe infections.

Background

Although considered a typical nosocomial pathogen for a long time, methicillin resistant Staphylococcus aureus (MRSA) has recently emerged as a cause of infections in the community. Most commonly, community-acquired (CA)-MRSA causes skin and soft-tissue infections [1, 2] while severe and life-threatening infections such as necrotizing pneumonia [3], necrotizing fasciitis [4] and severe sepsis [5] represent rare cases. CA-MRSA strains are globally spread but their prevalence and distribution vary from country to country [6]. In the United States, CA-MRSA isolates have become major community pathogens [1] and are starting to be introduced into the health-care system [7]. In that country, most of the recent CA-MRSA isolates belong to a single clone, that can be identified on the basis of Pulsed Field Gel Electrophoresis (PFGE) profile and other genotyping characteristics and is designed USA300 [2]. In Europe, the prevalence of infections due to CA-MRSA appears to be lower than in the United States, although recent reports highlight that these infections are on the rise. In a French hospital the incidence of skin and soft tissue infections due to CA-MRSA increased from 0% in 2000 to 6.8% in 2003 [8]. In Copenhagen the number of MRSA isolates, mainly obtained from community-acquired skin infections, doubled in less than 1 year, from 2003 to 2004) [9]. Differently from the situation in the United States where one clone predominates, CA-MRSA clones circulating in Europe are more diverse and heterogeneous [6].

In CA-MRSA isolates mec, the gene coding for methicillin resistance, is usually contained in the type IV variant of the genetic element staphylococcal chromosomal cassette (SCC)mec, that is smaller and probably more mobile than the other SCCmec elements [10]. CA-MRSA often contains the Panton-Valentine leukocidin (PVL), a toxin endowed with the unique ability to kill leukocytes [11]. PVL was initially associated with skin infections [12] and recently has been shown to play an essential role in the pathogenesis of necrotizing pneumonia [13].

We describe here an uncommon presentation of invasive CA-MRSA infection, with meningitis, bacteremia and necrotizing pneumonia in association with deep vein thrombosis, in a previously healthy adolescent.

Case presentation

A 15-year-old boy presented to the emergency department with a 4-day history of headache, fever, and lumbar pain and 1-day history of vomiting. His past clinical history was unremarkable, with the exception of mild asthma during childhood. Initial examination showed: temperature 40°C, heart rate 120 beats/min, respiratory rate 30 breaths/min, blood pressure 120/78 mmHg, mild disorientation (Glasgow Coma Scale 14) and meningeal signs. A small infiltrating skin lesion, partly crusted and partly purulent, was present on the back. The boy had been on a trekking vacation in Sicily and the lesion had been reportedly caused by the backpack on the bare skin. A chest radiogram showed bilateral multiple nodular infiltrates. Ultrasound examination of the abdomen revealed moderate enlargement of the liver and the spleen. A brain CT scan was normal. Analysis of blood samples at admission revealed a white blood cell count of 10,300 cells/mm3 with 86% polymorphonuclear leukocytes. Arterial blood gas analysis showed moderate hypoxemia (PaO2 of 73 mm Hg on room air). Blood cultures and a lumbar puncture were performed. Cerebrospinal fluid (CSF) examination revealed several red blood cells and a leukocyte count of 600 cells/ml, a protein level of 392 mg/dL, and a normal glucose level. Antibiotic therapy with clarithromycin and ceftriaxone was initiated and the patient was transferred to the Pediatric Intensive Care Unit (PICU) of another hospital, where his therapy was changed to ampicillin, doxicycline, ceftriaxone and acyclovir. Laboratories studies revealed a white blood cell count of 8,700 cells/mm3 with 84.8% polymorphonuclear leukocytes, platelet 130,000/mm3, C-reactive protein 187 mg/l (normal value < 3 mg/l), prothrombin time 20.90 sec, activated partial thromboplastin time 42 sec, international normalized ratio 1.57, fibrinogen 1060 mg/dL (normal range 200–400 mg/dL), antithrombin III 39.8% (normal range 70–120%), D-dimer > 4500 ng/ml (normal value < 278 ng/ml). The patient did not require mechanical ventilation and after 18 hours was discharged from the PICU and readmitted to the pediatric ward in stable conditions, conscious and still febrile to 40°C. Blood and CSF cultures from admission grew MRSA. Ampicillin was discontinued and vancomycin was added. Since fever persisted unabated, on day 5 the antibiotic therapy was switched to teicoplanin (400 mg iv twice a day), linezolid (600 mg iv twice a day) and rifampicin (600 mg iv once a day). A heart ultrasound revealed no valvular vegetations. A CT scan showed bilateral lung cavitary lesions suggesting multiple abscesses, bilateral pleural effusion (Fig. 1), thrombosis of the inferior vena cava below the renal veins, and of both iliac veins. Low molecular weight heparin was started. The patient demonstrated gradual clinical improvement, with slow normalization of temperature and C-reactive protein concentration. CT scan showed reduction of the nodular lesions and of the pleural effusion. Abdomen CT scan and echo-colour Doppler revealed resolution of the venous thrombosis. The patient completed a 5-week course of teicoplanin, rifampicin, and linezolid and was discharged home at day 40 in good general conditions. Anticoagulation was continued for a total of 6 months.
Figure 1

Chest CT of a patient with necrotizing pneumonia caused by CA-MRSA USA300 genotype. The CT scan, obtained on hospital day 5, shows multiple nodular lesions, some with a central cavitation, and bilateral pleural effusion.

Because of the unusual severity of the infection, underlying immunological or hematological defects were investigated. Quantitative immunoglobulins and subtypes, lymphocyte subtypes, and phagocyte function were normal. The presence of heterozygous factor V Leiden and prothrombin gene mutation (G20210A) was revealed.

Phenotypic and genotypic characterizations of MRSA

S. aureus was identified by standard microbiological methods. Antibiotic susceptibility testing was performed by BD Phoenix™ Automated Microbiology System (Beckton Dickinson) and confirmed by E-test (AB Biodisk, Solna, Sweden). The species identification and the methicillin resistance status were confirmed by a duplex PCR targeting the genes nuc and mec [14]. MRSA grew from the blood and CSF cultures obtained at admission and from a second blood culture performed after 48 h, before the institution of vancomycin therapy. The isolates were resistant to oxacillin but susceptible to non-beta-lactam antibiotics including erythromycin, clindamycin, ciprofloxacin, tetracycline, rifampicin, gentamicin, vancomycin, teicoplanin and linezolid. By E-test, the MIC for vancomycin was 2 μg/ml. Further characterization of the isolates was obtained by PCR assays and included determination of the SCCmec type, agr group, and presence of the PVL genes lukS-PV and lukF-PV [14]. Genotyping of the strains was obtained by PFGE, Multilocus Sequence Typing and by sequencing the polymorphic region of protein A (spa typing) as previously described [14]. The isolates from blood and CSF were identical by PFGE, and carried SCCmec type IV and the genes coding for PVL. Molecular typing showed that the strains were spa type t008, ST8 and agr type 1, characteristics shared by the USA300 CA-MRSA clone.

Conclusion

The development of a serious infection in a young person without predisposing conditions is a typical feature of CA-MRSA infections. However, to our knowledge, this is the first described case of CA-MRSA infection presenting with meningitis in an adolescent. The isolation of CA-MRSA from CSF is not common. CA-MRSA was isolated from the CSF of a 16-month-old child who died from fulminant sepsis. She had multiple abscesses in several organs, including the brain [15]. A case of CA-MRSA meningitis in an adult subject was mentioned in a study from Hong-Kong, but apart from the unfavorable outcome, clinical data are lacking [16]. Another fatal case recently reported, was that of a woman with a history of furunculosis and drug addiction, who developed a brain abscess due to CA-MRSA [17]. In our patient, meningeal symptoms were predominant at presentation, and the respiratory symptoms remained moderate in spite of the large involvement of the lungs as demonstrated by CT scan. The patient did not present airways hemorrhage, nor leukopenia, both factors being associated with fatal outcome in necrotizing pneumonia [18]. The skin infection on the patient's back might have represented the initial source for hematogenous spread of CA-MRSA, although microbiological examination of the purulent secretion was not performed.

Bacteremia due to typical CA-MRSA containing the PVL genes is rare but not exceptional, since typical CA-MRSA can be isolated from blood in the course of severe sepsis [5] or in other serious CA-MRSA infections in children and adolescents [19, 20]. In an unselected patient population, bloodstream infections due to PVL-positive CA-MRSA are very rare in Europe, as shown in a recent study from England [21] that included mainly isolates from elderly patients. In the USA, an increasing number of bloodstream infections in hospitalized patients is due to typical PVL-positive CA-MRSA [22], probably reflecting the introduction of the USA300 clone in the health-care setting in that country.

Another remarkable feature of this case is the association of the invasive CA-MRSA infection with deep venous thrombosis (DVT). DVT has been increasingly observed in children in association with osteomyelitis due to S. aureus containing the PVL genes [23]. Since the presence of PVL seems to be associated with greater systemic and local inflammation [20], it has been hypothesized that PVL could contribute substantially to the development of DVT. The expression "PVL syndrome" has been proposed to indicate a multifocal infection including osteomyelitis, skin infections, pneumonia, and DVT, due to PVL-positive S. aureus [24]. However, the association between PVL and DVT has been only observed in acute osteomyelitis and a causative role for PVL is unproven. In our patient, the CA-MRSA infection has uncovered inherited trombophilic defects, the factor V Leiden and the prothrombin gene mutation, that have determined the development of DVT, with or without the contribution of PVL. On the other hand, the presence of heterozygous factor V Leiden is known to confer protection in the septic state and decrease sepsis-related mortality [25], therefore it can have contributed to the favorable outcome of this case.

The CA-MRSA strain involved had genotypic characteristic (agr type 1, ST8, t008) of the USA300 clone that has become the predominant CA-MRSA clone in the USA. In Europe, the most common clone is the "European clone", characterized by agr type 3 and ST80 [26], and typically resistant to fusidic acid [27]. Recently, strains with the USA300 genotype are starting to be isolated with increasing frequency in various European countries [6]. In Germany, CA-MRSA isolates with the characteristics of the USA300 clone have become the second most frequent, after the ST80 isolates [28]. In Italy, a strain with the genotyping characteristics of the USA300 clone was recently recognized as the cause of a serious skin infection in a child [29].

The empirical therapy started for meningitis and community acquired pneumonia in this patient, that included ceftriaxone and clarithromycin, is ineffective against MRSA. In addition, ceftriaxone and beta-lactam antibiotics in general have been shown to increase the expression of PVL by S. aureus [30], thus potentially worsening the disease. When the results of the antibiotic susceptibility tests were available, vancomycin was started. However, since the vancomycin MIC of the isolate was at the breakpoint for susceptibility (2 μg/ml) and the patient's condition remained critical, a different antibiotic combination including linezolid was started. Linezolid was chosen because of its high antistaphylococcal activity, and its excellent CSF and lung tissue penetration. As in the previously described case of necrotizing pneumonia [14], linezolid therapy likely contributed to the favorable resolution of the CA-MRSA infection.

The antibiotic treatment of this patient raises several questions and reflects the lack of evidence-based data to guide the choice for the treatment of serious CA-MRSA infections. Vancomycin was used as the first-line treatment since it is effective against MRSA, and has been widely used in the past. Although vancomycin penetration in CSF is low, concentrations of 6–11 μg/ml are usually reached with inflamed meninges [31] and vancomycin is currently recommended in the antibiotic combination for the empirical treatment of bacterial meningitis [32]. The patient had also pneumonia and it is known that the levels reached by vancomycin in the lung compartment can be variable and insufficient for a bactericidal effect [31]. Poor penetration into the infected sites was a particularly critical issue in this case, since the MIC for vancomycin of the isolates was 2 μg/ml, that is still in the susceptibility range but close to the breakpoint. Clinical failures have been reported in serious infections due to MRSA with reduced susceptibility to vancomycin [33].

All the above conditions might have determined the lack of clinical improvement of the patient. Therefore, a new antibiotic combination was attempted, including teicoplanin, rifampicin and linezolid. Although there are few clinical studies relating to the use of teicoplanin in meningitis, in a rabbit model of MRSA meningitis the antibacterial activity of vancomycin and teicoplanin was shown to be similar [34]. Recent studies have shown the efficacy of linezolid in the treatment of patients with central nervous system infections [35] and pneumonia [36], its efficacy being at least equivalent and in some instances superior, to that of vancomycin. The drug combination was chosen based on the in vitro susceptibilities of the isolates but no adjunctive in vitro tests were performed to show whether the combination had synergistic, additive or antagonistic activity. There are no published clinical studies with this antibiotic combination to support the choice.

This case adds a new clinical presentation to CA-MRSA infections and highlights the problems encountered in the choice of the therapy of serious community-acquired infections in the CA-MRSA era.

Consent

Written informed consent was obtained from the patient's parent for publication of this case report and of the accompanying image. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Acknowledgements

This study was supported in part by a grant from the Italian Ministry of Education, Research and Technology (FIRB 2005).

Authors’ Affiliations

(1)
Istituto di Clinica Pediatrica, Università Cattolica del Sacro Cuore
(2)
Dipartimento dei Servizi, Azienda Ospedaliera San Camillo Forlanini
(3)
Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità
(4)
Istituto di Microbiologia, Università Cattolica del Sacro Cuore

References

  1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA: Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med. 2006, 355 (7): 666-674. 10.1056/NEJMoa055356View ArticlePubMedGoogle Scholar
  2. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM: Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med. 2006, 144 (5): 309-317.View ArticlePubMedGoogle Scholar
  3. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG: Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005, 40 (1): 100-107. 10.1086/427148View ArticlePubMedGoogle Scholar
  4. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005, 352 (14): 1445-1453. 10.1056/NEJMoa042683View ArticlePubMedGoogle Scholar
  5. Gonzalez BE, Martinez-Aguilar G, Hulten KG, Hammerman WA, Coss-Bu J, Avalos-Mishaan A, Mason EO, Kaplan SL: Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics. 2005, 115 (3): 642-648. 10.1542/peds.2004-2300View ArticlePubMedGoogle Scholar
  6. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, Reverdy ME, Enright MC, Vandenesch F, Etienne J: Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis. 2007, 13 (4): 594-600.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF, King MD, Ray SM, Blumberg HM: Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care–associated blood stream infections. Clin Infect Dis. 2006, 42: 647-656. 10.1086/499815View ArticlePubMedGoogle Scholar
  8. Del Giudice P, Blanc V, Durupt F, Bes M, Martinez JP, Counillon E, Lina G, Vandenesch F, Etienne J: Emergence of two populations of methicillin-resistant Staphylococcus aureus with distinct epidemiological, clinical and biological features, isolated from patients with community-acquired skin infections. Br J Dermatol. 2006, 154 (1): 118-124. 10.1111/j.1365-2133.2005.06910.xView ArticlePubMedGoogle Scholar
  9. Bartels MD, Boye K, Larsen AR, Skov R, Westh H: Rapid increase of genetically-diverse methicillin-resistant Staphylococcus aureus, Copenhagen, Denmark. Emerg Infect Dis. 2007, 13: 1533-1540.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Pantosti A, Sanchini A, Monaco M: Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2007, 2: 323-334. 10.2217/17460913.2.3.323View ArticlePubMedGoogle Scholar
  11. Boyle-Vavra S, Daum RS: Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2007, 87 (1): 3-9. 10.1038/labinvest.3700501View ArticlePubMedGoogle Scholar
  12. Yamasaki O, Kaneko J, Morizane S, Akiyama H, Arata J, Narita S, Chiba J, Kamio Y, Iwatsuki K: The association between Staphylococcus aureus strains carrying Panton-Valentine leukocidin genes and the development of deep-seated follicular infection. Clin Infect Dis. 2005, 40 (3): 381-385. 10.1086/427290View ArticlePubMedGoogle Scholar
  13. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Hook M, Etienne J, Vandenesch F, Bowden MG: Staphylococcus aureus Panton Valentine leukocidin causes necrotizing pneumonia. Science. 2007, 315: 1130-1133. 10.1126/science.1137165View ArticlePubMedGoogle Scholar
  14. Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A: Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg Infect Dis. 2005, 11 (10): 1647-1648.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Centers for Disease Control and Prevention (CDC): Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep. 1999, 48: 707-710.Google Scholar
  16. Ho PL, Cheung C, Mak GC, Tse CW, Ng TK, Cheung CH, Que TL, Lam R, Lai RW, Yung RW, Yuen KY: Molecular epidemiology and household transmission of community-associated methicillin-resistant Staphylococcus aureus in Hong Kong. Diagn Microbiol Infect Dis. 2007, 57 (2): 145-151. 10.1016/j.diagmicrobio.2006.08.003View ArticlePubMedGoogle Scholar
  17. Sifri CD, Park J, Helm GA, Stemper ME, Shukla SK: Fatal brain abscess due to community-associated methicillin-resistant Staphylococcus aureus strain USA300. Clin Infect Dis. 2007, 45 (9): e113-7. 10.1086/522171View ArticlePubMedGoogle Scholar
  18. Gillet Y, Venhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J: Factors predicting mortality in necrotizing community-acquired pneumonia caused by Panton-Valentine leukocidin. Clin Infect Dis. 2007, 45: 315-321. 10.1086/519263View ArticlePubMedGoogle Scholar
  19. Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS: Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med. 2005, 353 (12): 1245-1251. 10.1056/NEJMoa044194View ArticlePubMedGoogle Scholar
  20. Bocchini CE, Hulten KG, Mason EO, Gonzalez BE, Hammerman WA, Kaplan SL: Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics. 2006, 117 (2): 433-440. 10.1542/peds.2005-0566View ArticlePubMedGoogle Scholar
  21. Ellington MJ, Hope R, Ganner M, Ganner M, East C, Brick G, Kearns AM: Is Panton-Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK?. J Antimicrob Chemother. 2007, 60 (2): 402-405. 10.1093/jac/dkm206View ArticlePubMedGoogle Scholar
  22. Popovich KJ, Weinstein RA, Hota B: Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis. 2008, 46 (6): 787-794. 10.1086/528716View ArticlePubMedGoogle Scholar
  23. Gonzalez BE, Teruya J, Mahoney DH, Hulten KG, Edwards R, Lamberth LB, Hammerman WA, Mason EO, Kaplan SL: Venous thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. 2006, 117 (5): 1673-1679. 10.1542/peds.2005-2009View ArticlePubMedGoogle Scholar
  24. Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I: Fulminant methicillin-sensitive Staphylococcus aureus infection in a healthy adolescent, highlighting 'Panton-Valentine leucocidin syndrome'. Intern Med J. 2006, 36: 744-747. 10.1111/j.1445-5994.2006.01220.xView ArticlePubMedGoogle Scholar
  25. Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004, 32 (5 Suppl): S239-46. 10.1097/01.CCM.0000126122.34119.D1View ArticlePubMedGoogle Scholar
  26. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J: Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003, 9 (8): 978-984.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Witte W, Braulke C, Cuny C, Strommenger B, Werner G, Heuck D, Jappe U, Wendt C, Linde HJ, Harmsen D: Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis. 2005, 24 (1): 1-5. 10.1007/s10096-004-1262-xView ArticlePubMedGoogle Scholar
  28. Witte W, Strommenger B, Cuny C, Heuck D, Nuebel U: Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J Antimicrob Chemother. 2007, 60 (6): 1258-1263. 10.1093/jac/dkm384View ArticlePubMedGoogle Scholar
  29. Tinelli M, Pantosti A, Lusardi C, Vimercati M, Monaco M: First detected case of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infection in Italy. Euro Surveill. 2007, 12 (4): E0704121-Google Scholar
  30. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, Vandenesch F, Etienne J, Lina G: Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007, 51 (4): 1515-1519. 10.1128/AAC.01201-06PubMed CentralView ArticlePubMedGoogle Scholar
  31. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006, 42 Suppl 1: S35-9. 10.1086/491712View ArticlePubMedGoogle Scholar
  32. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ: Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004, 39 (9): 1267-1284. 10.1086/425368View ArticlePubMedGoogle Scholar
  33. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004, 38 (4): 521-528. 10.1086/381202View ArticlePubMedGoogle Scholar
  34. Sipahi OR, Arda B, Yurtseven T, Sipahi H, Ozgiray E, Suntur BM, Ulusoy S: Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis. Int J Antimicrob Agents. 2005, 26 (5): 412-415. 10.1016/j.ijantimicag.2005.08.011View ArticlePubMedGoogle Scholar
  35. Ntziora F, Falagas ME: Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother. 2007, 41 (2): 296-308. 10.1345/aph.1H307View ArticlePubMedGoogle Scholar
  36. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, Niki Y, Watanabe S, Furue M, Ito T, Croos-Dabrera R, Tack KJ: Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007, 60 (6): 1361-1369. 10.1093/jac/dkm369View ArticlePubMedGoogle Scholar

Copyright

© Valentini et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement